BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 25354239)

  • 1. A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease.
    Spinale JM; Mariani LH; Kapoor S; Zhang J; Weyant R; Song PX; Wong HN; Troost JP; Gadegbeku CA; Gipson DS; Kretzler M; Nihalani D; Holzman LB;
    Kidney Int; 2015 Mar; 87(3):564-74. PubMed ID: 25354239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating suPAR as a biomarker of disease severity in children with proteinuric glomerulonephritis.
    Sołtysiak J; Zachwieja J; Benedyk A; Lewandowska-Stachowiak M; Nowicki M; Ostalska-Nowicka D
    Minerva Pediatr; 2019 Feb; 71(1):4-11. PubMed ID: 27070416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.
    Huang J; Liu G; Zhang YM; Cui Z; Wang F; Liu XJ; Chu R; Zhao MH
    BMC Med; 2014 May; 12():81. PubMed ID: 24884842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble Urokinase Receptor Levels Are Correlated with Focal Segmental Glomerulosclerosis Lesions in IgA Nephropathy: A Cohort Study from China.
    Guo SM; Han M; Chen MX; Ning Y; Pei GC; Li YQ; Dai W; Ge SW; Deng YJ; Guo YY; Li XQ; Haller H; Xu G; Rong S
    PLoS One; 2015; 10(9):e0138718. PubMed ID: 26380984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS.
    Li F; Zheng C; Zhong Y; Zeng C; Xu F; Yin R; Jiang Q; Zhou M; Liu Z
    Clin J Am Soc Nephrol; 2014 Nov; 9(11):1903-11. PubMed ID: 25318750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease.
    Wada T; Nangaku M; Maruyama S; Imai E; Shoji K; Kato S; Endo T; Muso E; Kamata K; Yokoyama H; Fujimoto K; Obata Y; Nishino T; Kato H; Uchida S; Sasatomi Y; Saito T; Matsuo S
    Kidney Int; 2014 Mar; 85(3):641-8. PubMed ID: 24429394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates.
    Franco Palacios CR; Lieske JC; Wadei HM; Rule AD; Fervenza FC; Voskoboev N; Garovic VD; Zand L; Stegall MD; Cosio FG; Amer H
    Transplantation; 2013 Aug; 96(4):394-9. PubMed ID: 23736353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method.
    Winnicki W; Sunder-Plassmann G; Sengölge G; Handisurya A; Herkner H; Kornauth C; Bielesz B; Wagner L; Kikić Ž; Pajenda S; Reiter T; Schairer B; Schmidt A
    Sci Rep; 2019 Sep; 9(1):13783. PubMed ID: 31551522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis.
    Meijers B; Maas RJ; Sprangers B; Claes K; Poesen R; Bammens B; Naesens M; Deegens JK; Dietrich R; Storr M; Wetzels JF; Evenepoel P; Kuypers D
    Kidney Int; 2014 Mar; 85(3):636-40. PubMed ID: 24402090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels.
    Jin J; Li YW; He Q
    Transplant Proc; 2015; 47(6):1760-5. PubMed ID: 26293047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of the Japanese Biomarkers in Nephrotic Syndrome (J-MARINE) study.
    Kurasawa S; Kato S; Ozeki T; Akiyama S; Ishimoto T; Mizuno M; Tsuboi N; Kato N; Kosugi T; Maruyama S;
    Clin Exp Nephrol; 2024 May; 28(5):431-439. PubMed ID: 38267800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis.
    Musetti C; Quaglia M; Cena T; Chiocchetti A; Monti S; Clemente N; Magnani C; Dianzani U; Stratta P
    J Nephrol; 2015 Jun; 28(3):299-305. PubMed ID: 25185729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
    Chen JS; Chang LC; Wu CZ; Tseng TL; Lin JA; Lin YF; Cheng CW
    J Biomed Sci; 2016 Feb; 23():24. PubMed ID: 26846181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease.
    Mariani LH; Bomback AS; Canetta PA; Flessner MF; Helmuth M; Hladunewich MA; Hogan JJ; Kiryluk K; Nachman PH; Nast CC; Rheault MN; Rizk DV; Trachtman H; Wenderfer SE; Bowers C; Hill-Callahan P; Marasa M; Poulton CJ; Revell A; Vento S; Barisoni L; Cattran D; D'Agati V; Jennette JC; Klein JB; Laurin LP; Twombley K; Falk RJ; Gharavi AG; Gillespie BW; Gipson DS; Greenbaum LA; Holzman LB; Kretzler M; Robinson B; Smoyer WE; Guay-Woodford LM;
    Am J Kidney Dis; 2019 Feb; 73(2):218-229. PubMed ID: 30420158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance.
    Cara-Fuentes G; Wei C; Segarra A; Ishimoto T; Rivard C; Johnson RJ; Reiser J; Garin EH
    Pediatr Nephrol; 2014 Aug; 29(8):1363-71. PubMed ID: 24263531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma Soluble Urokinase Receptor Level Is Correlated with Podocytes Damage in Patients with IgA Nephropathy.
    Zhao Y; Liu L; Huang J; Shi S; Lv J; Liu G; Zhao M; Zhang H
    PLoS One; 2015; 10(7):e0132869. PubMed ID: 26167688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.
    Sinha A; Bajpai J; Saini S; Bhatia D; Gupta A; Puraswani M; Dinda AK; Agarwal SK; Sopory S; Pandey RM; Hari P; Bagga A
    Kidney Int; 2014 Mar; 85(3):649-58. PubMed ID: 24429405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis.
    Harita Y; Ishizuka K; Tanego A; Sugawara N; Chikamoto H; Akioka Y; Tsurumi H; Miura K; Gotoh Y; Tsujita M; Yamamoto T; Horike K; Takeda A; Oka A; Igarashi T; Hattori M
    Pediatr Nephrol; 2014 Sep; 29(9):1553-60. PubMed ID: 24705794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of proteinuria in primary glomerulonephritides: urinary polymers of albumin.
    Bazzi C; Petrini C; Rizza V; Arrigo G; Beltrame A; D'Amico G
    Am J Kidney Dis; 1997 Sep; 30(3):404-12. PubMed ID: 9292570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS?
    Schlöndorff D
    Kidney Int; 2014 Mar; 85(3):499-501. PubMed ID: 24583981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.